Tsung-Chih Chen

Tsung-Chih Chen

Auto-generated profile, based on publicly available information

Tsung-Chih Chen

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
HHHsu-Shan Huang
Hsu-Shan Huang
TCTsung-Chih Chen
Tsung-Chih Chen
RCRuei-Huei Chen
Ruei-Huei Chen
KHKuo-Feng Huang
Kuo-Feng Huang
FHFong-Chun Huang
Fong-Chun Huang
JLJing-Jer Lin
Jing-Jer Lin

1 September 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YLYu-Ru Lee
Yu-Ru Lee
TCTsung-Chih Chen
Tsung-Chih Chen
CLChia-Chung Lee
Chia-Chung Lee
CCChun-Liang Chen
Chun-Liang Chen
AAAhmed Atef Ahmed Ali
Ahmed Atef Ahmed Ali
Hsu-Shan HuangHsu-Shan Huang
Hsu-Shan Huang

1 June 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CLChia-Chung Lee
Chia-Chung Lee
FLFei-Lan Liu
Fei-Lan Liu
CCChun-Liang Chen
Chun-Liang Chen
TCTsung-Chih Chen
Tsung-Chih Chen
DCDeh-Ming Chang
Deh-Ming Chang
Hsu-Shan HuangHsu-Shan Huang
Hsu-Shan Huang

1 December 2011 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
YCYung-Lung Chang
Yung-Lung Chang
HLHwei-Jen Lee
Hwei-Jen Lee
SLShu-Ting Liu
Shu-Ting Liu
YLYu-Sheng Lin
Yu-Sheng Lin
TCTsung-Chih Chen
Tsung-Chih Chen
SHShih-Ming Huang
Shih-Ming Huang

1 February 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CCChun-Liang Chen
Chun-Liang Chen
DCDeh-Ming Chang
Deh-Ming Chang
TCTsung-Chih Chen
Tsung-Chih Chen
CLChia-Chung Lee
Chia-Chung Lee
HHHsi-Hsien Hsieh
Hsi-Hsien Hsieh
HHHsu-Shan Huang
Hsu-Shan Huang

30 June 2016 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
DWD-W Wu
D-W Wu
TCT-C Chen
T-C Chen
HHH-S Huang
H-S Huang
HLHuei Lee
Huei Lee
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) show a clinical benefit when used to treat patients with EGFR-mutated non-small-cell lung cancer (NSCLC), but this treatment unfortunately fails in patients with TKI-resistant tumors. We here provide evidence that TC-N19 (N19), a novel dual inhibitor of EGFR and cMET, efficiently overcomes the EGFR-TKI resistance in EGFR-mutated NSCLC cells via simultaneous degradation of both proteins by ubiquitin proteasomes. Comparison with HSP90 inhibitor treatment and knockdown of EGFR and cMET by small hairpin RNAs reveal that the reduction of EGFR and cMET expression by N19 is responsible for overcoming the intrinsic TKI resistance mediated by paxillin (PXN) in high PXN-expressing cells, PXN-overexpressing PC9 cells (PC9-PXN), the EGFR-T790M-mediated TKI resistance in H1975 and CL97 cells, and the acquired resistance to gefitinib in gefitinib-resistant PC9 cells (PC9GR). Annexin V-PI staining assay showed that the induction of apoptosis in NSCLC cells by N19 depended on the reduction in levels of both proteins. Xenograft tumor formation in nude mice induced by a PC9-PXN-stable clone and by PC9GR cells was nearly completely suppressed by N19 treatment, with no changes in animal body weight. MTT assays of normal lung cells and reticulocytes showed no cytotoxicity responses to N19. In summary, N19 may act as a novel dual inhibitor of EGFR and cMET that induces apoptosis in TKI-resistant EGFR-mutated NSCLC cells and suppresses xenograft tumor formation. We suggest that N19 may be a potential new-generation TKI or HSP90 inhibitor used for treatment of NSCLC patients who show resistance to current TKI-targeting therapies.